Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).

罗米普洛斯蒂姆 医学 安慰剂 血小板生成素 内科学 临床终点 人口 血小板 脾切除术 加药 随机对照试验 胃肠病学 病理 脾脏 替代医学 造血 环境卫生 生物 遗传学 干细胞
作者
Kôji Miyazaki,Yukari Shirasugi,Kiyoshi Ando,Yoshiaki Tomiyama,Shinichiro Okamoto,Mineo Kurokawa,Keita Kirito,Yuji Yonemura,Shin‐ichiro Mori,Kensuke Usuki,Koji Iwato,Satoshi Hashino,Helen Wei,Richard Lizambri
出处
期刊:Blood [Elsevier BV]
卷期号:116 (21): 3704-3704 被引量:1
标识
DOI:10.1182/blood.v116.21.3704.3704
摘要

Abstract Abstract 3704 Introduction: Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by both increased platelet destruction and decreased platelet production. Romiplostim increases platelet counts by binding and activating the thrombopoietin receptor. Romiplostim has been approved for the treatment of adult ITP in the United States, Europe, Canada, and Australia. This study evaluated dosing, efficacy, and safety in a Japanese population of adults with ITP. Methods: This phase 3 study was placebo-controlled, double-blind, and randomized 2:1 (romiplostim:placebo). Patients were eligible for the study if they were Japanese patients with ITP diagnosed at least 6 months before the initial screening, were aged ≥ 20 years, and were H pylori negative or had received at least 1 treatment for H pylori eradication. Patients were stratified by splenectomy status (yes or no). After a 3-week evaluation period, patients were treated for 12 weeks with a weekly subcutaneous injection of either romiplostim or placebo. The starting dose was 3 mcg/kg with dose adjustments to a maximum of 10 mcg/kg to achieve a platelet count within the target range of ≥ 50 to ≤ 200 × 109/L. Patients were monitored posttreatment until their platelet count dropped to ≤ 50 × 109/L or for a maximum of 12 weeks. The primary endpoint was number of weeks with platelet response (platelet count ≥ 50 × 109/L). Results: Thirty-four patients enrolled (22 romiplostim, 12 placebo), 24 (71%) were female, the median (range) age was 55 (44 - 64) years, and the median (range) baseline platelet count was 19 (3 – 32) × 109/L. Patients had received a median of 4 (1 – 19) prior ITP therapies, and 15 (44%) had previously undergone a splenectomy; 23 (68%) patients were receiving concurrent ITP therapy at baseline. All patients completed the study. Romiplostim demonstrated superiority to placebo on weekly platelet response, incidence of increase in platelet count ≥ 20 × 109/L from baseline, change from baseline in mean of last 4 platelet counts during week 2 to week 13, and number of weeks with platelet counts within the target range (Table 1), and 16 (73%) romiplostim patients had platelet counts ≥ 200 × 109/L. Twenty-one (95%) patients in the romiplostim group had a platelet response with a median time of 1 week until first response. Results for weekly platelet response were comparable irrespective of splenectomy status and baseline concurrent ITP therapy. Two (17%) patients in the placebo group achieved a platelet response. In romiplostim-treated patients, posttreatment platelet counts remained > 50 × 109/L for 8 weeks in one and for 12 weeks in another. The mean weekly dose of romiplostim for the study was 2.6 mcg/kg compared with the dose range of 3–4 mcg/kg in prior phase 3 studies (Kuter et al. Lancet. 2008;371:395–403). There was a low incidence of rescue medication use in the study (Table 1). The adverse events profile was comparable to that seen in non-Japanese studies. Patients in both treatment groups experienced similar proportions of adverse events (91% romiplostim, 92% placebo). Adverse events with > 10% higher frequency in the romiplostim group than placebo group) were (romiplostim, placebo) nasopharyngitis (41%, 17%), headache (32%, 17%), peripheral edema (18%, 0%), back pain (14%, 0%), and pain in extremity (14%, 0%). Significant (≥ grade 3) bleeding events occurred in 1 patient in the romiplostim group (subarachnoid hemorrhage) and 1 patient in the placebo group (subarachnoid hemorrhage, cerebral hemorrhage, and gastrointestinal hemorrhage). There were no adverse events of bone marrow reticulin, thrombosis, or detection of neutralizing antibodies. Conclusion: Romiplostim significantly increased and maintained platelet counts and was well-tolerated in a Japanese ITP population. Disclosures: Tomiyama: Kyowa Hakko Kirin Co.: Speakers Bureau; GlaxoSmithKline: Speakers Bureau. Kurokawa:Novartis: Consultancy; Shionogi & Co., Ltd.: Consultancy. Wei:Amgen Inc.: Employment, Equity Ownership. Lizambri:Amgen Inc.: Employment, Equity Ownership.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈苗发布了新的文献求助10
刚刚
完美世界应助卡皮巴拉采纳,获得10
刚刚
万能图书馆应助Muhammad采纳,获得10
1秒前
1秒前
2秒前
FashionBoy应助阿九采纳,获得10
2秒前
朗读卿完成签到 ,获得积分10
3秒前
星辰大海应助纳兰若微采纳,获得100
4秒前
大气傲易完成签到 ,获得积分10
5秒前
1111发布了新的文献求助10
5秒前
5秒前
帅男发布了新的文献求助10
6秒前
深味i完成签到,获得积分10
6秒前
8秒前
宇宙无敌完成签到 ,获得积分10
9秒前
小二郎应助jundading采纳,获得10
9秒前
9秒前
10秒前
笑点低的傲旋完成签到,获得积分20
10秒前
jingxian发布了新的文献求助10
11秒前
11秒前
11秒前
充电宝应助努力采纳,获得10
11秒前
CodeCraft应助Rony采纳,获得10
11秒前
懒羊羊完成签到,获得积分10
14秒前
liuwenwen发布了新的文献求助10
14秒前
14秒前
15秒前
16秒前
七十二发布了新的文献求助10
16秒前
yeye发布了新的文献求助10
17秒前
17秒前
YAMO一发布了新的文献求助10
18秒前
18秒前
卡皮巴拉发布了新的文献求助10
18秒前
Jasper应助Muhammad采纳,获得10
19秒前
科研通AI2S应助陈曦采纳,获得10
20秒前
顾霜凌发布了新的文献求助10
21秒前
小蘑菇应助鱼与木头采纳,获得10
21秒前
江沅发布了新的文献求助10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989660
求助须知:如何正确求助?哪些是违规求助? 3531826
关于积分的说明 11255082
捐赠科研通 3270447
什么是DOI,文献DOI怎么找? 1804981
邀请新用户注册赠送积分活动 882136
科研通“疑难数据库(出版商)”最低求助积分说明 809176